Health-related quality of life in patients with recurrent pericarditis: results from a phase 2 study of rilonacept
Open Access
- 21 April 2021
- journal article
- research article
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 21 (1) , 1-14
Abstract
Background: Impact of recurrent pericarditis (RP) on patient health-related quality of life (HRQoL) was evaluated through qualitative patient interviews and as an exploratory endpoint in a Phase 2 trial evaluating the efficacy and safety of rilonacept (IL-1α/IL-1β cytokine trap) to treat RP. Methods: Qualitative interviews were conducted with ten adults with RP to understand symptoms and HRQoL impacts, and the 10-item Patient-Reported Outcomes Measurement Information System Global Health (PROMIS GH) v1.2 was evaluated to determine questionnaire coverage of patient experience. The Phase 2 trial enrolled participants with active symptomatic RP (A-RP, n = 16) and corticosteroid-dependent participants with no active recurrence at baseline (CSD-RP, n = 9). All participants received rilonacept weekly during a 6-week base treatment period (TP) plus an optional 18-week extension period (EP). Tapering of concomitant medications, including corticosteroids (CS), was permitted during EP. HRQoL was assessed using the PROMIS GH, and patient-reported pain and blood levels of c-reactive protein (CRP) were collected at Baseline and follow-up periods. A secondary, descriptive analysis of the Phase 2 trial efficacy results was completed using HRQoL measures to characterize both the impact of RP and the treatment effect of rilonacept. Results: Information from qualitative interviews demonstrated that PROMIS GH concepts are relevant to adults with RP. From the Phase 2 trial, both participant groups showed impacted HRQoL at Baseline (mean PROMIS Global Physical Health [GPH] and Global Mental Health [GMH], were lower than population norm average). In A-RP, GPH/MPH improved by end of base TP and were sustained through EP (similar trends were observed for pain and CRP). Similarly, in CSD-RP, GPH/MPH improved by end of TP and further improved during EP, during CS tapering or discontinuation, without disease recurrence (low pain scores and CRP levels continued during the TP and EP). Conclusion: This is the first study demonstrating impaired HRQoL in RP. Rilonacept treatment was associated with HRQoL improvements using PROMIS GH scores. Maintained/improved HRQoL during tapering/withdrawal of CS without recurrence suggests that rilonacept may provide an alternative to CS. Trial registration: ClinicalTrials.Gov; NCT03980522; 5 June 2019, retrospectively registered; https://clinicaltrials.gov/ct2/show/NCT03980522.Keywords
All Related Versions
Funding Information
- Kiniksa Pharmaceuticals, Ltd.
This publication has 28 references indexed in Scilit:
- The effect of corticosteroids on quality of life in a sarcoidosis clinic: The results of a propensity analysisRespiratory Medicine, 2015
- Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short‐Form McGill Pain Questionnaire (SF‐MPQ), Chronic Pain Grade Scale (CPGS), Short Form‐36 Bodily Pain Scale (SF‐36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP)Arthritis Care & Research, 2011
- Pericardial Disease: Diagnosis and ManagementMayo Clinic Proceedings, 2010
- Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global itemsQuality of Life Research, 2009
- Corticosteroids for Recurrent PericarditisCirculation, 2008
- Pain measurement in patients with low back painNature Clinical Practice Rheumatology, 2007
- Core outcome measures for chronic pain clinical trials: IMMPACT recommendationsPain, 2005
- Relapsing pericarditisHeart, 2004
- Recurrent pericarditis in children and adolescentsJACC, 2003
- Linking clinical variables with health-related quality of life. A conceptual model of patient outcomesJAMA, 1995